This includes design, development and testing of products specific to NIAID Category A-C priority areas.

1. High titer/concentrated Vaccinia Immune Globulin (VIG) or replacement product based on monoclonal antibodies (Mabs)
   
   
2. Botulinum antitoxin including:
   • safe and effective alternatives to toxoid vaccine
   • monoclonal antibodies
   • polyclonal antibodies
   
   
3. Development of an alternative vaccine against smallpox that could be delivered to those at high risk of serious complications to the current vaccinia vaccine (e.g., MVA)
   
   
4. Second generation anthrax vaccines (e.g., rPA)
   
   
5. Ebola and Marburg hemorrhagic fever vaccines
   
   
6. Tularemia vaccines
   
   
7. Plague vaccines
   
   
8. Rift Valley Fever vaccines
   
   
9. Cell culture (e.g. Vero cells) based vaccines for influenza
   
   
10. Antivirals for smallpox and viral hemorrhagic fevers
    
    
11. Arenavirus and specific viral encephalitis vaccines (e.g., Tickborne encephalitis viruses, West Nile virus, Eastern equine encephalitis virus, Western equine encephalitis virus)